Drug companies reach $2.15B settlement in patent-infringement case

06/13/2013 | Wall Street Journal, The

Takeda Pharmaceutical and Pfizer will receive a total of $2.15 billion as part of a settlement reached with generic-drug manufacturers in a patent-infringement case. The damages stem from an "at-risk" launch of a generic substitute for the heartburn drug Protonix. In an at-risk launch, a generic-drug company begins selling a generic medication while patent litigation is still underway. The strategy can backfire if a drug patent is later found to be valid, which is what happened in this case.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Business

Job Title Company Location
Manager, Technical Staffing
U.S. Cellular
Chicago, IL
Human Resource Director
Confidential
Salt Lake City, UT
Vice-President of Global Sales
Lindsay Corporation
Hartland, WI
Chief Operations Officer
Delta Community Supports
Blue Bell, PA
Administrative Management Specialist
Smithsonian Institute
Washington, DC